Business Wire

RAK-GOV-MEDIA-OFFICE

Share
A Journey Through Time: The Evolution of Ras Al Khaimah Art

Steeped in 7,000 years of history, the UAE’s ‘Nature Emirate’ Ras Al Khaimah is undergoing an unprecedented period of economic growth, with tourism, real estate and sustainability taking center stage. Within this dynamic ecosystem, Ras Al Khaimah Art has flourished to become the Emirate’s landmark celebration of culture and the arts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312427377/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Featuring works from 107 local and international artists and welcoming 45,000 visitors from around the world, Ras Al Khaimah Art 2024 has successfully concluded its 12th edition at the restored Al Jazeera Al Hamra Heritage Village. Launching as a three-day art exhibition in 2013, Ras Al Khaimah Art has evolved into a month-long annual event and the UAE’s largest outdoor art festival, showcasing Ras Al Khaimah’s vibrant cultural heritage and reflecting the Emirate’s unprecedented cross-sector economic growth. (Photo: AETOSWire)

Inspired by the vision of H.H. Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, the festival was conceived to showcase the Emirate’s artistic talent and foster cultural exchange. Launching at Ras Al Khaimah’s National Museum in 2013 as a three-day exhibition, Ras Al Khaimah Art has evolved into a month-long annual event, welcoming 106 local and international artists from 35 countries in 2024, alongside 45,000 visitors.

Vision & Teamwork
Founding Executive Director of the Al Qasimi Foundation and Ras Al Khaimah Art organiser, Dr. Natasha Ridge acknowledged the event’s potential early on and explored avenues for expansion. During a visit to La Gacilly in France, she encountered a village transformed into an outdoor art gallery and envisioned a similar concept for Ras Al Khaimah Art: “I knew the perfect place.”

Listed on UNESCO’s tentative list of World Heritage Sites, Al Jazeera Al Hamra Heritage Village is the UAE’s last-surviving pearl-fishing village, representing centuries of architecture, trade and culture. Encompassing a fort, watchtowers, a mosque, souq and traditional dwellings, the magical site is defined by a labyrinth of stone alleyways and today, by Ras Al Khaimah Art.

“It’s not just an art festival, it’s also a historical site, which attracts a much wider audience,” says Dr. Ridge.

Ras Al Khaimah Art’s repertoire has expanded to include a range of artistic expressions, from workshops and film screenings to live performances and an art exploration program. “Last year, we saw 1000 students participate in workshops and tours. By connecting our youth with history and culture, we adopt a sustainable approach to the arts,” says Dr. Ridge.

Cultivating Global Connections
Ras Al Khaimah Art plays a pivotal role in promoting Ras Al Khaimah as a cultural destination. By providing a platform for local artists alongside international counterparts, Ras Al Khaimah Art also contributes to the cultural and economic progress of the UAE.

Read more: www.rakart.ae/2024-festival

Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240312427377/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release

Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release

The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye